Top

Published in:

01-05-2010 | Original Article

A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer

Authors: Jin Young Kim, Young Rok Do, Keon Uk Park, Min Kyung Kim, Kyung Hee Lee, Sung Hwa Bae, Hun Mo Ryoo, Jin Ho Baek, Hong Suk Song

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2010

Abstract

Objective

The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer.

Methods

Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m² and cisplatin 70 mg/m² were intravenously given on day 1 of 21 days schedule.

Results

From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients.

Conclusion

Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer.

Korean National Cancer Center (2007) Korean central cancer registry 22nd annual report. http://www.ncc.re.kr

Ajani JA, Ilson DH, Daugherty K et al (1994) Activity in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091CrossRefPubMed

Coonley CJ, Bains M, Heelan R et al (1983) Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67:397–398PubMed

Ajani JA (1994) Contribution of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 21:474–482PubMed

Polee MB, Eskens FA, van der Burg ME et al (2002) Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 86:669–673CrossRefPubMed

Mauer A, Haraf D, Ferguson M et al (2000) Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia (abstract 954). Proc Ann Meet Am Soc Clin Oncol 19:246a

Einzig AL, Neuberg D, Remick SC et al (1996) Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology group (ECOG) results of protocol E1293. Med Oncol 13:87–93CrossRefPubMed

Heath EJ, Urba S, Marshall J et al (2002) Phase II trial of docetaxel chemotherapy in patient with incurable adenocarcinoma of the esophagus. Invest New Drugs 20:95–99CrossRefPubMed

Woo IS, Jung KH, Park YL et al (1996) 5-Fluorouracil and cisplatin (FP) combination chemotherapy in advanced esophageal cancer. Korean Cancer Assoc 28:835–841

10.

Bleiberg H, Conroy T, Paillot B et al (1997) Randomized phases II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell esophageal cancer. Eur J Cancer 33:1216–1220CrossRefPubMed

11.

Sparreboom A, van Tellingen O, Nooijen WJ et al (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1–17CrossRefPubMed

12.

Metges J, Hennequin C, Ychou M et al. (2001) Docetaxel as a second-line chemotherapy in metastatic esophageal cancer: a French study. Proc Am Soc Clin Oncol 20: 160a (Abstract 635)

13.

Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955–959CrossRefPubMed

14.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92:205–216CrossRefPubMed

15.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10CrossRefPubMed

16.

Long DL, Duffey PL, DeVita VT Jr et al (1991) The calculation of actual or received dose intensity; a comparison of published methods. J Clin Oncol 9:2042–2051

17.

Jatoi A, Tirona MT, Cha SS et al (2002) A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 32:115–123CrossRefPubMed

18.

Lordick F, von Schilling C, Bernhard H et al (2003) Phase II trial of irinotecn plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancer. Br J Cancer 89:630–633CrossRefPubMed

19.

Petrasch S, Welt A, Reinacher A et al (1998) Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic esophageal cancer. Br J Cancer 78:511–514PubMed

20.

Ilson DH, Ajani J, Ahalla K et al (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826–1834PubMed

21.

Fosella FV, Lee JS, Murphy WK et al (1994) Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238–1244

22.

Laack E, Andritzky B, Durk H et al (2005) Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 28:647–650CrossRefPubMed

23.

Lorenzen S, Duyster J, Lersch C et al (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92:2129–2133CrossRefPubMed

Title: A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
Authors: Jin Young Kim
Young Rok Do
Keon Uk Park
Min Kyung Kim
Kyung Hee Lee
Sung Hwa Bae
Hun Mo Ryoo
Jin Ho Baek
Hong Suk Song
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1130-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

Effects of extracellular purines on cytotoxicity of methotrexate

The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer